Patient data
| Characteristic . | Total (N = 146) . |
|---|---|
| Median age, y (range) | 37.9 (2.3-67.0) |
| Male, no. (%) | 80 (55) |
| CMV serostatus before transplantation, no. (%) | |
| Recipient CMV-positive | 146 (100) |
| Donor CMV-positive | 97 (66) |
| Disease stage at transplantation, no. (%) | |
| CML chronic phase | 44 (30) |
| Hematologic malignancy first remission | 17 (12) |
| Hematologic malignancy other than first remission | 70 (48) |
| Other | 15 (10) |
| HLA donor matching, no. (%) | |
| Matched related | 75 (51) |
| Mismatched related | 20 (14) |
| Unrelated | 51 (35) |
| Conditioning therapy, no. (%) | |
| Cyclophosphamide plus TBI | 63 (43) |
| Busulfan + cyclophosphamide | 48 (33) |
| Other | 35 (24) |
| GVHD prophylaxis, no. (%) | |
| CSA plus methotrexate | 92 (63) |
| Other | 54 (37) |
| GVHD incidence, no. (%)* | |
| Acute, grades 2-4 | 115 (80) |
| Acute, grades 3-4 | 102 (71) |
| Chronic, clinical-extensive | 86 (60) |
| Ganciclovir use before d 80, no. (%) | |
| At engraftment | 60 (41) |
| At pp65 antigenemia, as strategy | 86 (59) |
| pp65 antigenemia, actually present | 55 (38) |
| None | 31 (21) |
| Lymphopenia between d 40 and 95 after HSCT | |
| Fewer than 100 lymphocytes/mm3 | 80 (55) |
| Fewer than 300 lymphocytes/mm3 | 137 (94) |
| CD4 counts at baseline less than 50 cells/mm3 | 57 (43)† |
| CD8 counts at baseline less than 50 cells/mm3 | 44 (33)† |
| CMV disease before study entry, no. (%) | 3 (2) |
| Characteristic . | Total (N = 146) . |
|---|---|
| Median age, y (range) | 37.9 (2.3-67.0) |
| Male, no. (%) | 80 (55) |
| CMV serostatus before transplantation, no. (%) | |
| Recipient CMV-positive | 146 (100) |
| Donor CMV-positive | 97 (66) |
| Disease stage at transplantation, no. (%) | |
| CML chronic phase | 44 (30) |
| Hematologic malignancy first remission | 17 (12) |
| Hematologic malignancy other than first remission | 70 (48) |
| Other | 15 (10) |
| HLA donor matching, no. (%) | |
| Matched related | 75 (51) |
| Mismatched related | 20 (14) |
| Unrelated | 51 (35) |
| Conditioning therapy, no. (%) | |
| Cyclophosphamide plus TBI | 63 (43) |
| Busulfan + cyclophosphamide | 48 (33) |
| Other | 35 (24) |
| GVHD prophylaxis, no. (%) | |
| CSA plus methotrexate | 92 (63) |
| Other | 54 (37) |
| GVHD incidence, no. (%)* | |
| Acute, grades 2-4 | 115 (80) |
| Acute, grades 3-4 | 102 (71) |
| Chronic, clinical-extensive | 86 (60) |
| Ganciclovir use before d 80, no. (%) | |
| At engraftment | 60 (41) |
| At pp65 antigenemia, as strategy | 86 (59) |
| pp65 antigenemia, actually present | 55 (38) |
| None | 31 (21) |
| Lymphopenia between d 40 and 95 after HSCT | |
| Fewer than 100 lymphocytes/mm3 | 80 (55) |
| Fewer than 300 lymphocytes/mm3 | 137 (94) |
| CD4 counts at baseline less than 50 cells/mm3 | 57 (43)† |
| CD8 counts at baseline less than 50 cells/mm3 | 44 (33)† |
| CMV disease before study entry, no. (%) | 3 (2) |